Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases

In the present study we evaluated how systemic arterial hypertension (SAH), dyslipidemia and diabetes mellitus influence the efficacy, safety and retention rate of biological disease-modifying anti-rheumatic drug (bDMARD) treatment in rheumatic musculoskeletal disorders (RMDs). The charts of RMD pat...

Full description

Bibliographic Details
Main Authors:	Laura Cometi, Cosimo Bruni, Nicolò Chiti, Lorenzo Tofani, Francesca Nacci, Francesca Bartoli, Silvia Bellando-Randone, Daniela Melchiorre, Ginevra Fiori, Serena Guiducci, Marco Matucci-Cerinic
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	Journal of Clinical Medicine
Subjects:	arterial hypertension dyslipidemia bDMARDs rheumatoid arthritis psoriatic arthritis ankylosing spondylitis
Online Access:	https://www.mdpi.com/2077-0383/9/5/1310

Similar Items

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
by: Eleni Kampylafka, et al.
Published: (2018-07-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study
by: Muhammad Haroon, et al.
Published: (2018-04-01)

Demographic, clinical and radiological characteristics of seronegative spondyloarthritis Egyptian patients: A rheumatology clinic experience in Mansoura
by: Adel Abdelsalam, et al.
Published: (2017-04-01)

Bone phenotypes in rheumatology – there is more to bone than just bone
by: Christian S. Thudium, et al.
Published: (2020-11-01)

Comorbidities in inflammatory joint and spine diseases in XXI century
by: I Z Gaydukova, et al.
Published: (2018-12-01)

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients
by: Chen HH, et al.
Published: (2017-05-01)

Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
by: Jozélio Freire de Carvalho, et al.
Published: (2018-08-01)

Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
by: Joshua L. Lee, et al.
Published: (2018-08-01)

IL-23 and Th17 Disease in Inflammatory Arthritis
by: Toru Yago, et al.
Published: (2017-08-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases
by: Hermine Leroi, et al.
Published: (2020-05-01)

Diagnosis of spondyloarthritis: should we need new criteria?
by: I. Z. Gaidukova, et al.
Published: (2015-03-01)

«TREAT-TO-TARGET» (T2T) STRATEGY IN SPONDYLOARTHRITIS
by: Sh. F. Erdes
Published: (2014-06-01)

Prevalence of spondyloarthritis and its subtypes - are they really comparable?
by: Zlatković-Švenda Mirjana I., et al.
Published: (2019-01-01)

Demographic, clinical, laboratory and treatment characteristics of spondyloarthritis patients with and without acute anterior uveitis
by: Marcelo Gehlen, et al.

Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study
by: Deepak R. Jadon, et al.
Published: (2017-09-01)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
by: Paloma Vela, et al.
Published: (2020-06-01)

Significance of asymptomatic hyperuricemia in ankylosing spondylitis
by: R. M. Balabanova, et al.
Published: (2021-06-01)

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
by: Katarzyna Bogunia-Kubik, et al.
Published: (2021-07-01)

Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Philip Brenner, et al.
Published: (2020-02-01)

Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
by: Santhi Mantravadi, et al.
Published: (2020-09-01)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
by: Svedbom A, et al.
Published: (2017-01-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience
by: Piet L.C.M. van Riel
Published: (2016-01-01)

Changing the concept of spondyloarthritis: Characteristics of teaching when changing the paradigm in a particular area of medical knowledge
by: I. Z. Gaydukova, et al.
Published: (2017-04-01)

Comparative analysis between ankylosing spondylitis and axial psoriatic arthritis patients
by: Marwa Mahmoud Abdelaziz, et al.
Published: (2022-01-01)

Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis
by: Gustavo Citera, et al.
Published: (2021-01-01)

Vitamin D and Seronegative Spondylarthritis
by: Panagiotis Athanassiou, et al.
Published: (2016-01-01)

Letter to the editor re: prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis
by: Rodrigo Garcia-Salinas, et al.
Published: (2021-05-01)

Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases
by: Aikaterini Arida, et al.
Published: (2018-06-01)

Imaging of juvenile spondyloarthritis. Part I: Classifications and radiographs
by: Iwona Sudoł-Szopińska, et al.
Published: (2017-09-01)

Classifications and imaging of juvenile spondyloarthritis
by: Iwona Sudoł-Szopińska, et al.
Published: (2018-09-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis
by: Dennis McGonagle, et al.
Published: (2021-03-01)

Recommendation for the Management of Spondyloarthritis Patients in Kuwait
by: Ali Y, et al.
Published: (2020-08-01)

Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study
by: Jesus Miguens Blanco, et al.
Published: (2020-11-01)

Cannot write session to /tmp/vufind_sessions/sess_6i0vpo2qp246m2uqrv087ujbuv